Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Diabetes Discourse

The Benefits of TZDs for Early Type 2 Diabetes

11 Mar 2010

Description

Host: Steven Edelman, MD Guest: John (Jack) L. Leahy, MD Where do thiazolidinediones, or TZD's, fit in our clinical approach to treating patients with type 2 diabetes? TZD's used early in the course of the disease seem to be a powerful therapy with a substantial reduction in the progression of type 2 diabetes. What does this tell us about the pathogenesis of diabetes? Join host Dr. Steven Edelman and his guest, professor of medicine and chief of the division of endocrinology, diabetes and metabolism of the University of Vermont, Dr. Jack Leahy, as they discuss the pathogenesis of diabetes and the role of thiazolidinediones in the prevention and treatment of type 2 diabetes.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.